Head-to-head · Cost-Efficiency Index
MaxLife vs Coivas
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
MaxLife
Cost-first shoppers who want new patients specifically chasing the current limited-time promo, not for shoppers wanting stable published pricing.
Visit MaxLifeCoivas
Shoppers wanting a named, verifiable prescribing physician (NPI-checkable) behind a nationwide compounded GLP-1 service.
Visit CoivasThe verdict
MaxLife and Coivas tie on the Cost-Efficiency Index at 58/100, so neither wins outright on the numbers. For most shoppers we'd start with MaxLife (ranked #280, a hair above #284) — Cost-first shoppers who want new patients specifically chasing the current limited-time promo, not for shoppers wanting stable published pricing. But Coivas is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs MaxLife.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | MaxLife | Coivas |
|---|---|---|
| Cost-Efficiency Index | 58/100 | 58/100 |
| Semaglutide / mo | $169/mo (compounded) | $119/mo (starting dose, compounded) |
| Tirzepatide / mo | $169/mo (compounded) | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $2,028 | $1,428 |
| Tirzepatide / yr (modeled) | $2,028 | $2,388 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #280 | #284 |
MaxLife
58/100Where the value is
- Low advertised entry price ($169) plus a free first week for new clients
- Clear phone and email contact information for direct follow-up
- Simple, straightforward homepage messaging
The tradeoffs
- Headline price is explicitly a rotating seasonal promo ('March special'), not a stable rate
- No ongoing/renewal price disclosed anywhere after the promo period
Regulatory note: the FDA issued a warning letter to MaxLife Technologies Inc. dba Maxlife in February 2026. We still list and link to MaxLife; you should know the letter is on the public record before you decide.
Coivas
58/100Where the value is
- Named prescribing physician with checkable NPI (Dr. Sean Arora, NPI 1841729449)
- LegitScript approval seal displayed
- Claims availability in all 50 states
The tradeoffs
- 'Starting at' pricing could not be confirmed as the genuine ongoing rate -- pricing subpages were unreachable (404)
- No single named compounding pharmacy -- varies by location/medication
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.